Arch Therapeutics, Inc.
ARTH · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $7 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 383.8% | 35.3% | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.2% | -229% | -127.3% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,129.6% | -30,064% | -52,636.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,221.4% | -27,318.3% | -56,802.8% | – |
| EPS Diluted | -2.27 | -3.56 | -5.97 | -4.27 |
| % Growth | 36.2% | 40.4% | -39.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |